CLINICAL_TRIALS
withdrawal
· 2016-11-02
Clinical Trial Update: A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]
Summary
A Phase 2 clinical trial evaluating oral vismodegib for idiopathic pulmonary fibrosis has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hoffmann-La Roche | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: WITHDRAWN